155 related articles for article (PubMed ID: 1437337)
21. Lung function in prematurely delivered rabbits treated with a synthetic surfactant.
Tooley WH; Clements JA; Muramatsu K; Brown CL; Schlueter MA
Am Rev Respir Dis; 1987 Sep; 136(3):651-6. PubMed ID: 3307569
[TBL] [Abstract][Full Text] [Related]
22. Exosurf treatment investigational new drug phase: effect of an individualized third dose in infants with respiratory distress syndrome.
Easa D; Pelke S; Nakamura KT; Barrett J; Balaraman V; Loo SW; Ibarra-Pratt E; Smith MB
Pediatr Pulmonol; 1992 Sep; 14(1):16-22. PubMed ID: 1437338
[TBL] [Abstract][Full Text] [Related]
23. A controlled trial of synthetic surfactant in infants weighing 1250 g or more with respiratory distress syndrome. The American Exosurf Neonatal Study Group I, and the Canadian Exosurf Neonatal Study Group.
Long W; Corbet A; Cotton R; Courtney S; McGuiness G; Walter D; Watts J; Smyth J; Bard H; Chernick V
N Engl J Med; 1991 Dec; 325(24):1696-703. PubMed ID: 1944470
[TBL] [Abstract][Full Text] [Related]
24. Postnatal changes in pulmonary mechanics and energetics of infants with respiratory distress syndrome following surfactant treatment.
Bhutani VK; Bowen FW; Sivieri EM
Biol Neonate; 2005; 87(4):323-31. PubMed ID: 15985755
[TBL] [Abstract][Full Text] [Related]
25. Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity.
Modanlou HD; Beharry K; Padilla G; Norris K; Safvati S; Aranda JV
J Perinatol; 1997; 17(6):455-60. PubMed ID: 9447532
[TBL] [Abstract][Full Text] [Related]
26. [Use of Exosurf Neonatal, a synthetic surfactant, in the treatment of respiratory distress syndrome in the newborn].
Mikhel'sonVA ; Grebennikov VA; Belaĭ VA; Everstova TN
Anesteziol Reanimatol; 1995; (1):4-7. PubMed ID: 7605034
[TBL] [Abstract][Full Text] [Related]
27. Effect of single dose surfactant on pulmonary function.
Bhat R; Dziedzic K; Bhutani VK; Vidyasagar D
Crit Care Med; 1990 Jun; 18(6):590-5. PubMed ID: 2111754
[TBL] [Abstract][Full Text] [Related]
28. Effects of exogenous surfactant therapy on dynamic compliance during mechanical breathing in preterm infants with hyaline membrane disease.
Couser RJ; Ferrara TB; Ebert J; Hoekstra RE; Fangman JJ
J Pediatr; 1990 Jan; 116(1):119-24. PubMed ID: 2404097
[TBL] [Abstract][Full Text] [Related]
29. Comparison of clinical responses to natural and synthetic surfactants.
Rollins M; Jenkins J; Tubman R; Corkey C; Wilson D
J Perinat Med; 1993; 21(5):341-7. PubMed ID: 8126629
[TBL] [Abstract][Full Text] [Related]
30. Partial liquid ventilation in premature lambs with respiratory distress syndrome: efficacy and compatibility with exogenous surfactant.
Leach CL; Holm B; Morin FC; Fuhrman BP; Papo MC; Steinhorn D; Hernan LJ
J Pediatr; 1995 Mar; 126(3):412-20. PubMed ID: 7869204
[TBL] [Abstract][Full Text] [Related]
31. Modified bovine surfactant (Survanta) versus a protein-free surfactant (Exosurf) in the treatment of respiratory distress syndrome in preterm infants: a pilot study.
Sehgal SS; Ewing CK; Richards T; Taeusch HW
J Natl Med Assoc; 1994 Jan; 86(1):46-52. PubMed ID: 8151722
[TBL] [Abstract][Full Text] [Related]
32. Early versus delayed neonatal administration of a synthetic surfactant--the judgment of OSIRIS. The OSIRIS Collaborative Group (open study of infants at high risk of or with respiratory insufficiency--the role of surfactant.
Lancet; 1992 Dec; 340(8832):1363-9. PubMed ID: 1360087
[TBL] [Abstract][Full Text] [Related]
33. Criteria for use of colfosceril (Exosurf) in neonates.
Bhatt-Mehta V; Schumacher RE
Clin Pharm; 1992 Apr; 11(4):355-7. PubMed ID: 1563234
[No Abstract] [Full Text] [Related]
34. Double-blind, randomized, placebo-controlled Canadian multicenter trial of two doses of synthetic surfactant or air placebo in 224 infants weighing 500 to 749 grams with respiratory distress syndrome. Canadian Exosurf Neonatal Study Group.
Smyth J; Allen A; MacMurray B; Peliowski A; Sankaran K; Volberg F; Shukla A; Long W
J Pediatr; 1995 May; 126(5 Pt 2):S81-9. PubMed ID: 7745516
[TBL] [Abstract][Full Text] [Related]
35. Exosurf treatment following wood smoke inhalation.
Feldbaum DM; Wormuth D; Nieman GF; Paskanik M; Clark WR; Hakim TS
Burns; 1993 Oct; 19(5):396-400. PubMed ID: 8216766
[TBL] [Abstract][Full Text] [Related]
36. [Outcome of blood gas parameters during the first 24 years after Exosurf administration].
Lenoir S; Grandjean H; Claris O; Hascoët JM
Arch Pediatr; 1996 Apr; 3(4):324-8. PubMed ID: 8762952
[TBL] [Abstract][Full Text] [Related]
37. Effects of aerosolized artificial surfactant on repeated oleic acid injury in sheep.
Zelter M; Escudier BJ; Hoeffel JM; Murray JF
Am Rev Respir Dis; 1990 Apr; 141(4 Pt 1):1014-9. PubMed ID: 2327634
[TBL] [Abstract][Full Text] [Related]
38. Changes in pulmonary artery pressure in infants with respiratory distress syndrome following treatment with Exosurf.
Hamdan AH; Shaw NJ
Arch Dis Child Fetal Neonatal Ed; 1995 May; 72(3):F176-9. PubMed ID: 7796233
[TBL] [Abstract][Full Text] [Related]
39. Reduced mortality in small premature infants treated at birth with a single dose of synthetic surfactant.
Corbet AJ; Long WA; Murphy DJ; Garcia-Prats JA; Lombardy LR; Wold DE
J Paediatr Child Health; 1991 Aug; 27(4):245-9. PubMed ID: 1958425
[TBL] [Abstract][Full Text] [Related]
40. Respiratory distress syndrome in New Zealand: evidence from the OSIRIS trial of exogenous surfactant (Exosurf).
Wach R; Darlow B; Bourchier D; Broadbent R; Knight D; Selby R
N Z Med J; 1994 Jun; 107(980):234-7. PubMed ID: 8208494
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
